These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 26545048)

  • 1. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
    Cahill DP; Louis DN; Cairncross JG
    CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
    Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
    J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligodendrogliomas: new insights from the genetics and perspectives.
    Alentorn A; Sanson M; Idbaih A
    Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.
    Chan AK; Pang JC; Chung NY; Li KK; Poon WS; Chan DT; Shi Z; Chen L; Zhou L; Ng HK
    Mod Pathol; 2014 Mar; 27(3):332-42. PubMed ID: 24030748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
    Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
    Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
    Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
    Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas.
    Padul V; Epari S; Moiyadi A; Shetty P; Shirsat NV
    Genes Chromosomes Cancer; 2015 Dec; 54(12):725-33. PubMed ID: 26357005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts.
    Lee J; Putnam AR; Chesier SH; Banerjee A; Raffel C; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Perry A; Solomon DA
    Acta Neuropathol Commun; 2018 Sep; 6(1):95. PubMed ID: 30231927
    [No Abstract]   [Full Text] [Related]  

  • 11. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
    Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
    J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
    Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
    Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent oligodendroglioma with changed 1p/19q status.
    Barresi V; Mafficini A; Calicchia M; Piredda ML; Musumeci A; Ghimenton C; Scarpa A
    Neuropathology; 2022 Apr; 42(2):160-166. PubMed ID: 35144313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
    Sathornsumetee S; Cheunsuchon P; Sangruchi T
    World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.
    Baumgarten P; Harter PN; Tönjes M; Capper D; Blank AE; Sahm F; von Deimling A; Kolluru V; Schwamb B; Rabenhorst U; Starzetz T; Kögel D; Rieker RJ; Plate KH; Ohgaki H; Radlwimmer B; Zörnig M; Mittelbronn M
    Neuropathol Appl Neurobiol; 2014 Feb; 40(2):205-16. PubMed ID: 24117486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
    Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
    Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
    Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
    Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas.
    Xu J; Xu FP; Liu ZH; Cui Q; Zhang KP; Li Z
    Medicine (Baltimore); 2022 Jul; 101(29):e29668. PubMed ID: 35866817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.